Human papillomavirus (HPV) is responsible for cervical cancer, and its role in head and neck carcinoma has been reported. No drug is approved for the treatment of HPV-related diseases but cidofovir (CDV) exhibits selective antiproliferative activity. In this study, we analyzed the effects of CDV-resistance (CDVR) in two HPV(+) (SiHaCDV and HeLaCDV) and one HPV(-) (HaCaTCDV) tumor cell lines. Quantification of CDV metabolites and analysis of the sensitivity profile to chemotherapeutics was performed. Transporters expression related to multidrug-resistance (MRP2, P-gp, BCRP) was also investigated. Alterations of CDV metabolism in SiHaCDV and HeLaCDV, but not in HaCaTCDV, emerged via impairment of UMP/CMPK1 activity. Mutations (P64T and R134M) as well as down-regulation of UMP/CMPK1 expression were observed in SiHaCDV and HeLaCDV, respectively. Altered transporters expression in SiHaCDV and/or HeLaCDV, but not in HaCaTCDV, was also noted. Taken together, these results indicate that CDVR in HPV(+) tumor cells is a multifactorial process.

Institute of Organic Chemistry and Biochemistry Academy of Sciences of The Czech Republic v v i Prague Czech Republic

Rega Institute for Medical Research KU Leuven Leuven Belgium

Sorbonne Universités UPMC University Paris 06 UMR 8256 B2A Biological Adaptation and Ageing Integrated Cellular Ageing and Inflammation Molecular and Functional Enzymology Paris France

Zobrazit více v PubMed

Snoeck R, De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr Opin Investig Drugs. 2002;3:1561–1566. PubMed

Kirsch LS, Arevalo JF, Chavez dlP, Munguia D, De Clercq E, Freeman WR. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology. 1995;102:533–542. PubMed

Andrei G, Fiten P, Goubau P, van Landuyt H, Gordts B, Selleslag D, De Clercq E, Opdenakker G, Snoeck R. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Transpl Infect Dis. 2007;9:126–131. doi: 10.1111/j.1399-3062.2006.00186.x. PubMed DOI

De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. Biochem Pharmacol. 2011;82:99–109. doi: 10.1016/j.bcp.2011.03.027. PubMed DOI

Snoeck R, Andrei G, Gerard M, Silverman A, Hedderman A, Balzarini J, Sadzot-Delvaux C, Tricot G, Clumeck N, De Clercq E. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) Clin Infect Dis. 1994;18:570–578. PubMed

Snoeck R, Andrei G, De Clercq E. Specific therapies for human papilloma virus infections. Curr Opin Infect Dis. 1998;11:733–737. PubMed

Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013;19:6473–6483. doi: 10.1158/1078-0432.CCR-13-1121. PubMed DOI PMC

Liekens S, Verbeken E, De Clercq E, Neyts J. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int J Cancer. 2001;92:161–167. PubMed

Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res. 1998;58:384–388. PubMed

Yang Y, Zhao X, Chen W, Gao Z, Liu A, Guo J, Yan Z, Dou Y, Wang H, Li Y. Effects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude mice. Oncol Res. 2010;18:519–527. PubMed

Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12:397–408. PubMed

De Schutter T, Andrei G, Topalis D, Naesens L, Snoeck R. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med Genomics. 2013;6:18. doi: 10.1186/1755-8794-6-18. PubMed DOI PMC

Andrei G, Topalis D, De Schutter T, Snoeck R. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia. Antiviral Res. 2015;114C:21–46. doi: 10.1016/j.antiviral.2014.10.012. PubMed DOI

Alexandre JA, Roy B, Topalis D, Pochet S, Perigaud C, Deville-Bonne D. Enantioselectivity of human AMP, dTMP and UMP-CMP kinases. Nucleic Acids Res. 2007;35:4895–4904. doi: 10.1093/nar/gkm479. PubMed DOI PMC

Pasti C, Gallois-Montbrun S, Munier-Lehmann H, Veron M, Gilles AM, Deville-Bonne D. Reaction of human UMP-CMP kinase with natural and analog substrates. Eur J Biochem. 2003;270:1784–1790. PubMed

Topalis D, Kumamoto H, Amaya Velasco MF, Dugue L, Haouz A, Alexandre JA, Gallois-Montbrun S, Alzari PM, Pochet S, Agrofoglio LA, Deville-Bonne D. Nucleotide binding to human UMP-CMP kinase using fluorescent derivatives– a screening based on affinity for the UMP-CMP binding site. FEBS J. 2007;274:3704–3714. doi: 10.1111/j.1742-4658.2007.05902.x. PubMed DOI

Deville-Bonne D, El Amri C, Meyer P, Chen Y, Agrofoglio LA, Janin J. Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties. Antiviral Res. 2010;86:101–120. doi: 10.1016/j.antiviral.2010.02.001. PubMed DOI

Van Rompay AR, Johansson M, Karlsson A. Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme. Mol Pharmacol. 1999;56:562–569. PubMed

Xu Y, Johansson M, Karlsson A. Human UMP-CMP kinase 2, a novel nucleoside monophosphate kinase localized in mitochondria. J Biol Chem. 2008;283:1563–1571. doi: 10.1074/jbc.M707997200. PubMed DOI

Liou JY, Dutschman GE, Lam W, Jiang Z, Cheng YC. Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res. 2002;62:1624–1631. PubMed

Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–598. doi: 10.1038/nrc3342. PubMed DOI

O'Connor R. The pharmacology of cancer resistance. Anticancer Res. 2007;27:1267–1272. PubMed

Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol. 2012;83:1041–1048. doi: 10.1016/j.bcp.2011.12.025. PubMed DOI PMC

Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875–890. PubMed

Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res. 2002;26:621–629. PubMed

Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ, Cass CE, Gros P. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 2008;68:2349–2357. doi: 10.1158/0008-5472.CAN-07-5528. PubMed DOI

Mata JF, Scrideli CA, Queiroz RP, Mori BO, Emerenciano M, Pombo-de-Oliveira MS, Tone LG. Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia. Braz J Med Biol Res. 2006;39:1417–1423. PubMed

Song JH, Kim SH, Kweon SH, Lee TH, Kim HJ, Kim HJ, Kim TS. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int J Oncol. 2009;34:1165–1171. PubMed

Connelly MC, Robbins BL, Fridland A. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem Pharmacol. 1993;46:1053–1057. PubMed

Salphati L, Plise EG, Li G. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513. Eur J Pharm Sci. 2009;37:463–468. doi: 10.1016/j.ejps.2009.04.001. PubMed DOI

Tiwari AK, Zhang R, Gallo JM. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. Mol Cancer Ther. 2013;12:1343–1355. doi: 10.1158/1535-7163.MCT-13-0100. PubMed DOI PMC

Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL. Expression of drug pathway proteins is independent of tumour type. J Pathol. 2006;209:213–219. doi: 10.1002/path.1955. PubMed DOI

Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem. 1990;265:16617–16625. PubMed

Hu R, Lam W, Hsu CH, Cheng YC. UMP/CMPK is not the critical enzyme in the metabolism of pyrimidine ribonucleotide and activation of deoxycytidine analogs in human RKO cells. PLoS One. 2011;6:e19490. doi: 10.1371/journal.pone.0019490. PubMed DOI PMC

Liou JY, Lai HR, Hsu CH, Chang WL, Hsieh MJ, Huang YC, Cheng YC. Modulation of human UMP/CMP kinase affects activation and cellular sensitivity of deoxycytidine analogs. Biochem Pharmacol. 2010;79:381–388. doi: 10.1016/j.bcp.2009.09.010. PubMed DOI

Okajima T, Fukamizo T, Goto S, Fukui T, Tanizawa K. Exchange of nucleoside monophosphate-binding domains in adenylate kinase and UMP/CMP kinase. J Biochem. 1998;124:359–367. PubMed

Segura-Pena D, Sekulic N, Ort S, Konrad M, Lavie A. Substrate-induced conformational changes in human UMP/CMP kinase. J Biol Chem. 2004;279:33882–33889. doi: 10.1074/jbc.M401989200. PubMed DOI

Dahnke T, Tsai MD. Mechanism of adenylate kinase. The conserved aspartates 140 and 141 are important for transition state stabilization instead of substrate-induced conformational changes. J Biol Chem. 1994;269:8075–8081. PubMed

Dallas S, Schlichter L, Bendayan R. Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia. J Pharmacol Exp Ther. 2004;309:1221–1229. doi: 10.1124/jpet.103.063966. PubMed DOI

Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem. 2003;278:29509–29514. doi: 10.1074/jbc.M304059200. PubMed DOI

Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K, Belinsky MG. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr. 2001;33:493–501. PubMed

Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst. 2000;92:1934–1940. PubMed

Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH, Schuetz JD. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4:E14. doi: 10.1208/ps040314. PubMed DOI PMC

Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther. 2001;299:567–574. PubMed

Connelly MC, Robbins BL, Fridland A. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem Pharmacol. 1993;46:1053–1057. PubMed

Hampson L, Martin-Hirsch P, Hampson IN. An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia. Expert Opin Investig Drugs. 2015;24:1529–1537. doi: 10.1517/13543784.2015.1099628. PubMed DOI

Henken FE, Banerjee NS, Snijders PJ, Meijer CJ, De-Castro AJ, Rosl F, Broker TR, Chow LT, Steenbergen RD. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Mol Cancer. 2011;10:71. doi: 10.1186/1476-4598-10-71. PubMed DOI PMC

De Schutter T, Andrei G, Topalis D, Duraffour S, Mitera T, van den Oord J, Matthys P, Snoeck R. Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir. Mol Cancer. 2013;12:158. doi: 10.1186/1476-4598-12-158. PubMed DOI PMC

Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res. 1998;10:523–531. PubMed

Blondin C, Serina L, Wiesmuller L, Gilles AM, Barzu O. Improved spectrophotometric assay of nucleoside monophosphate kinase activity using the pyruvate kinase/lactate dehydrogenase coupling system. Anal Biochem. 1994;220:219–221. doi: 10.1006/abio.1994.1326. PubMed DOI

El Amri C, Martin AR, Vasseur JJ, Smietana M. Borononucleotides as substrates/binders for human NMP kinases: enzymatic and spectroscopic evaluation. Chembiochem. 2012;13:1605–1612. doi: 10.1002/cbic.201200199. PubMed DOI

Zhong L, Johnson WC., Jr Environment affects amino acid preference for secondary structure. Proc Natl Acad Sci U S A. 1992;89:4462–4465. PubMed PMC

Xanthine-based acyclic nucleoside phosphonates with potent antiviral activity against varicella-zoster virus and human cytomegalovirus